Literature DB >> 3465243

CA 125: a useful marker in endometrial carcinoma.

J M Duk, J G Aalders, G J Fleuren, H W de Bruijn.   

Abstract

In a retrospective study 121 patients with endometrial cancer were examined. In addition, 20 primary endometrial adenocarcinomas were tested immunohistochemically for CA 125. All tumor tissues were demonstrated to contain CA 125. However, only 25% of 110 patients had elevated CA 125 levels in serum before treatment. The incidence of elevated CA 125 serum levels increased with higher tumor staging up to 55% and 86% in surgical Stages III and IV, respectively. In Stage I and II disease (International Federation of Gynecology and Obstetrics) elevated serum levels before treatment correlated with the presence of tumor tissues outside the uterine body or outside the uterus, respectively, as was determined histopathologically after operation. In addition a close correlation between elevated levels and vessel invasion of tumor cells was revealed. Serum levels of CA 125 paralleled the clinical course of disease. Tumor recurrence in the abdomen can be preceded by an increase of serum CA 125 levels.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3465243     DOI: 10.1016/0002-9378(86)90358-3

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  32 in total

1.  Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer.

Authors:  A Stiekema; Car Lok; C M Korse; W J van Driel; V van der Noort; G G Kenter; K K Van de Vijver
Journal:  Virchows Arch       Date:  2017-04-11       Impact factor: 4.064

2.  Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma.

Authors:  Gloria S Huang; Lydia G Chiu; Juliana S Gebb; Marc J Gunter; Paniti Sukumvanich; Gary L Goldberg; Mark H Einstein
Journal:  Gynecol Oncol       Date:  2007-10-23       Impact factor: 5.482

3.  CA 125 in normal tissues and carcinomas of the uterine cervix, endometrium and fallopian tube. I. Immunohistochemical detection.

Authors:  A Scharl; G Crombach; M Vierbuchen; H Müsch; A Bolte
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

4.  CA 125 in normal tissues and carcinomas of the uterine cervix, endometrium and Fallopian tube. II. Immunoradiometric determination in secretions, tissue extracts and serum.

Authors:  G Crombach; A Scharl; H Würz
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

5.  CA 125 and CA 19-9 in peritoneal, cyst and amniotic fluids.

Authors:  P Inaudi; L Pasqui; G C Torre; F M Severi; G Centini; W Gioffré; S Danero; N D'Antona
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

6.  Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer.

Authors:  Eleftheria Kalogera; Nathalie Scholler; Cecelia Powless; Amy Weaver; Ronny Drapkin; Jinping Li; Shi-Wen Jiang; Karl Podratz; Nicole Urban; Sean C Dowdy
Journal:  Gynecol Oncol       Date:  2011-10-28       Impact factor: 5.482

7.  Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.

Authors:  Chad M Michener; Gertrude Peterson; Barbara Kulp; Kenneth D Webster; Maurie Markman
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

8.  Involvement of ovarian factors magnified by pharmacological induction of multiple follicular development (MFD) in the increase in Ca125 occurring during the luteal phase and the first 12 weeks of induced pregnancies.

Authors:  A M Paoletti; G G Serra; V Mais; S Ajossa; S Guerriero; M Orrù; G B Melis
Journal:  J Assist Reprod Genet       Date:  1995-04       Impact factor: 3.412

Review 9.  The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.

Authors:  Archana R Simmons; Keith Baggerly; Robert C Bast
Journal:  Oncology (Williston Park)       Date:  2013-06       Impact factor: 2.990

10.  Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer.

Authors:  Pedro F Escobar; Maurie Markman; Kristine Zanotti; Kenneth Webster; Jerome Belinson
Journal:  J Cancer Res Clin Oncol       Date:  2003-09-23       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.